0:00 21世纪经济报道 记者凌晨 一场围绕"重组胶原蛋白"的行业对决，将两位区域女首富与其上市公司推向台前。陕西范代娣领导的巨 子生物曾是赛道标杆，而山西杨霞执掌的锦波生物正通过新品牌"同频"跨界切入C端护肤市场。 战事首先在电商直播间打响。同频在李佳琦直播间快速崛起，今年双十一李佳琦首场直播中GMV增速 位列第二。同时，一向低调的锦波生物创始人杨霞罕见为同频站台，被视为其从B端药械进军C端美妆 的明确信号。 从胶原蛋白药械到美妆，锦波的降维入场，无疑对主攻C端的巨子，形成正面冲击。同样的流量带货手 法、同类型的产品，锦波能否凭借医药背景实现超车，将决定胶原蛋白市场下一阶段的格局走向。 ...

Core Viewpoint - The recent announcement by Jinbo Biotechnology regarding its plan to issue shares to Yangshengtang highlights the growing interest and investment in the recombinant collagen market, which is experiencing rapid growth in China's medical aesthetics sector [1][2]. Company Summary - Jinbo Biotechnology plans to issue up to 7.1756 million shares at a price of 278.72 yuan per share, raising a total of no more than 2 billion yuan for the development of a humanized collagen FAST database and product development platform [1]. - The company has received three Class III medical device registration certificates for its recombinant collagen products, positioning it as a leader in the medical aesthetics field [3]. - The recent transfer of shares from the controlling shareholder to Hangzhou Jiushi indicates a strategic move to strengthen ties with major players in the industry [1]. Industry Summary - The medical aesthetics market in China is experiencing strong and diverse demand, with the recombinant collagen product market projected to grow from 19.24 billion yuan in 2022 to over 58.57 billion yuan by 2025, and further to 219.38 billion yuan by 2030, reflecting a compound annual growth rate of 44.93% [2]. - The market is seeing an influx of new products, with multiple companies obtaining Class III medical device approvals, indicating a vibrant and competitive landscape [3][4]. - The prevalence of illegal medical aesthetics institutions has surpassed legal ones, with 22,000 illegal institutions compared to 20,000 legal ones, raising concerns about consumer safety and market integrity [6]. Market Dynamics - The high prices of medical aesthetics services in China are driving consumers towards illegal options, as many perceive the costs of legitimate services to be prohibitively high compared to those in markets like South Korea and Hong Kong [7]. - The introduction of competitively priced products, such as New Oxygen's "Miracle Youth 3.0" priced at 2,999 yuan, aims to make compliant medical aesthetics more accessible and reduce the appeal of illegal services [7]. - The industry is characterized by a "new is better" mentality, where new products can quickly saturate the market, leading to price reductions and potential volatility in consumer preferences [5].

Core Viewpoint - The stock of Giant Bio has seen a significant increase, with a rise of over 5% in early trading, currently priced at 57.80 HKD, with a trading volume of 392 million HKD. The company reported a revenue of approximately 3.113 billion HKD for the first half of the year, reflecting a year-on-year growth of 22.5%, and a net profit attributable to shareholders of approximately 1.182 billion HKD, up 20.2% year-on-year [1]. Financial Performance - Giant Bio's revenue for the first half of the year is approximately 3.113 billion HKD, representing a year-on-year increase of 22.5% [1]. - The net profit attributable to the parent company is around 1.182 billion HKD, showing a year-on-year growth of 20.2% [1]. Analyst Insights - CICC maintains its profit forecast for Giant Bio at 2.5 billion HKD and 3.2 billion HKD for the years 2025 and 2026, respectively [1]. - The current stock price corresponds to a price-to-earnings (P/E) ratio of 21x and 17x for the years 2025 and 2026 [1]. - CICC has reiterated its "outperform" rating and target price of 82 HKD, indicating a potential upside of 50% based on a P/E ratio of 32x and 25x for the years 2025 and 2026 [1]. Market Outlook - With the Double Eleven shopping festival approaching, an increase in marketing frequency is expected to drive brand awareness and customer acquisition, potentially restoring growth momentum for the brand [1].

美银证券发布研报称，巨子生物(02367)上半年业绩略超预期，总收入31.13亿元人民币，同比增长 22.5%。该行基于上半年表现及今年7月强劲的线上表现，上调公司旗下品牌可复美(Comfy)的收入预 测，并将2025至2027年的总收入预测各上调1.9%。此外，因巨子生物的直播收入贡献降低，下调2025 年销售费用比率;将2025至207年每股盈利预测分别上调2%、1.7%及1.7%。对其目标价由79港元微升至 79.5港元，重申"买入"评级，因为重组胶原蛋白产品的增长可见度高。 ...

Core Insights - Jinbo Bio reported a significant increase in net profit for 2024, with a year-on-year growth of 144.27% [1] - The company's operating revenue reached 1.44 billion, marking an 84.92% increase compared to the previous year [1] - The gross profit margin improved to 92.02%, up by 1.86 percentage points from the previous year [2] Financial Performance - Operating revenue for 2024 was 1,442,831,399.69, compared to 780,260,212.25 in 2023, reflecting an 84.92% increase [1] - Net profit attributable to shareholders was 732,301,620.38, a 144.27% increase from 299,796,292.39 in 2023 [1] - The net profit after deducting non-recurring gains and losses was 712,180,480.92, up 149.15% from 285,842,673.17 in the previous year [1] - Basic earnings per share rose to 8.27, a 131.65% increase from 3.57 in 2023 [1] Cost and Expenses - Total period expenses for 2024 were 467 million, an increase of 114 million from the previous year [2] - The expense ratio decreased to 32.40%, down by 12.86 percentage points compared to the previous year [2] - Sales expenses increased by 56.73%, while management expenses rose by 38.08% [2] - Research and development expenses decreased by 16.20%, and financial expenses fell by 5.46% [2] Employee Statistics - The total number of employees increased to 823 in 2024, up from 730 in the previous year, representing a 13.29% growth [3] Leadership and Governance - The chairman of Jinbo Bio, Yang Xia, received a salary of 2.2 million in 2024, a decrease of 18.46% from 2.698 million in 2023 [4] - The company has a diverse leadership team with various educational backgrounds, including PhDs and master's degrees [3][5] Company Overview - Jinbo Bio, established on March 28, 2008, specializes in the research, production, and sales of medical devices and functional skincare products, focusing on recombinant collagen products and anti-HPV biological protein products [5]

Core Insights - Jinbo Bio announced two significant transactions, including a strategic investment from Yangshengtang, which involves issuing up to 7.1757 million shares, representing 6.24% of the pre-issue total share capital, to raise no more than 2 billion yuan, potentially marking the largest cash private placement in the history of the Beijing Stock Exchange [1] - The controlling shareholder Yang Xia signed a share transfer agreement with Hangzhou Jiushi, transferring 5.7533 million shares at a price of 243.84 yuan per share, totaling 1.403 billion yuan [4] - The ultimate controllers of both Yangshengtang and Hangzhou Jiushi are Zhong Shanshan, who has invested 3.4 billion yuan into Jinbo Bio [5] Financial Performance - Following Zhong Shanshan's investment, Jinbo Bio's stock price surged, with a total market capitalization exceeding 40.3 billion yuan, trading at 350.55 yuan, up 0.5% [7] - As of March 31, 2025, Jinbo Bio reported cash and cash equivalents of 959 million yuan, indicating a slight increase from 941 million yuan at the end of 2024 [10] Strategic Implications - The introduction of Yangshengtang as a strategic investor is expected to empower Jinbo Bio in various aspects, including product development, industrial production, commercialization, market strategy, and management, thereby addressing capacity construction and product commercialization challenges [10] - The collaboration signifies a notable shift in the competitive landscape of the medical aesthetics industry, with Jinbo Bio aiming to enhance its market position through this partnership [11]

Group 1 - Qiyunshan Food Co., Ltd. submitted its prospectus to the Hong Kong Stock Exchange on June 27, aiming to expand its e-commerce network and enhance online promotion [1] - Qiyunshan holds a 32.4% market share in China's sour jujube food market, making it the industry leader [1] - The company plans to leverage its capital operations to increase brand influence and product value, although public awareness of sour jujube remains low [1] Group 2 - Jinbo Biological, a leading collagen company, disclosed a private placement plan to raise up to 2 billion yuan by issuing shares to Yangshengtang Co., Ltd. [2] - After the issuance, Yangshengtang will hold over 5% of Jinbo Biological, becoming its second-largest shareholder [2] - The collaboration is expected to enhance Jinbo Biological's brand promotion and product management, aligning well with Yangshengtang's anti-aging cosmetics focus [2] Group 3 - The China Consumers Association advocated against food waste and extreme eating broadcasts, emphasizing the importance of frugality and food conservation [3] - The association proposed a "three-party governance" approach involving consumers, content creators, and platform operators to foster a healthy online food environment [3] - This initiative reflects a strong sense of responsibility towards food security and social civility [3]

Market Overview - The Hong Kong stock market experienced a significant rise, with the Hang Seng Index increasing by 2.06%, the Hang Seng Tech Index by 2.14%, and the Hang Seng China Enterprises Index by 1.9% [2] - The technology, financial, and automotive sectors saw widespread gains, while oil and gas stocks faced substantial declines [2] Technology and Financial Stocks - Major technology and financial stocks rose, with Xiaomi increasing nearly 4%, Hongye Futures surging over 15%, and China Galaxy rising nearly 9% [3] - Leading insurance stocks included China Taiping and Ping An, while major banks like Bank of Communications, China Construction Bank, and Industrial and Commercial Bank of China reached new highs [3] Oil and Gas Sector - The oil and gas sector suffered due to a sharp decline in international oil prices, influenced by geopolitical developments in the Middle East [4] - Notable declines included United Energy Group falling over 21%, Sinopec Oilfield Services down 15.85%, and Dalip Holdings dropping over 10% [4][5] Automotive Sector - The automotive sector benefited from favorable market conditions, with significant gains in stocks such as BYD (up 3.25%), Li Auto (up 3.81%), and Leap Motor (up 4.34%) [6][7] - The China Association of Automobile Manufacturers reported that vehicle production and sales in the first five months of the year increased by over 10% year-on-year, with new energy vehicles showing particularly strong growth [8] Company-Specific Developments - Juzhibio saw a rise of 5.27% following a statement addressing the limitations of its current collagen product testing methods [9] - The company acknowledged the need for improved quality standards and testing methods in response to industry advancements and consumer expectations [11][13] - Future measures include collaborating with research institutions to enhance testing methods, publicly sharing key technical parameters, and participating in the formulation of national and industry standards [14]

Group 1: Market Overview - The Hong Kong stock market opened high and closed with significant gains, with the Hang Seng Index rising by 2.06%, the Hang Seng Tech Index by 2.14%, and the Hang Seng China Enterprises Index by 1.9% [2] - The technology and financial sectors saw widespread gains, while the oil and gas sector experienced a sharp decline [2][3] Group 2: Technology and Financial Stocks - Major technology and financial stocks rose, with Xiaomi increasing nearly 4%, Hongye Futures soaring over 15%, and China Galaxy rising nearly 9% [4] - Leading insurance stocks included China Taiping and Ping An, while major banks like CCB, ICBC, and CMB reached new highs [4][5] Group 3: Oil and Gas Sector - The oil and gas sector faced significant sell-offs due to a sharp drop in international oil prices, with companies like United Energy Group falling over 21% and Sinopec Oilfield Services down 15.85% [6][7] - Specific stock performances included China Petroleum down 0.30%, Sinopec Oilfield Services down 15.85%, and United Energy Group down 21.21% [8] Group 4: Automotive Sector - The automotive sector benefited from favorable market conditions, with stocks like BYD rising 3.25%, Li Auto up 3.81%, and Leap Motor increasing 4.34% [9][10] - The overall automotive industry showed positive growth, with production and sales in the first five months of the year increasing by over 10% year-on-year, and new energy vehicle sales reaching 44% of total new car sales [12] Group 5: Company-Specific News - Juzhibio saw a rise of 5.27% following a statement addressing the limitations of its current collagen product testing methods [13][14] - The company acknowledged the need for optimization in quality standards and testing methods to meet industry advancements and consumer expectations [18]

Group 1 - The core issue revolves around the dispute between two major players in the medical beauty industry, Juzi Biotechnology and Huaxi Biotechnology, regarding recombinant collagen products [2] - Juzi Biotechnology acknowledged limitations in its current quality standards, testing methods, and labeling, which are not fully aligned with the industry's evolving high standards and technological advancements [2][7] - Following the announcement, Juzi Biotechnology's stock price surged over 7% on June 24 [3] Group 2 - Juzi Biotechnology outlined three future initiatives: collaborating with research institutions to enhance testing methods for recombinant collagen in cosmetics, gradually disclosing key technical parameters and quality control data, and actively participating in the formulation of national and industry standards for recombinant collagen [7] - Huaxi Biotechnology previously addressed concerns about the lack of relevant testing standards in the recombinant collagen sector, emphasizing the misuse of the term "collagen" and the need for clear scientific conclusions to avoid misleading the market and consumers [10]